AmacaThera announces Phase 1 clinical trial for non-opioid, post-operative pain management

Ontario Industry Updates
Written By Maura Campbell
AmacaThera.jpg

AmacaThera Inc. announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain.

Maura Campbell
Previous

Updates on Canada’s New Substances Notifications Regulations (Organisms)
Next

Mediphage Bioceuticals appoints Alvaro Amorrortu as chief executive officer and president